Dramatic response to brigatinib in a lung adenocarcinoma patient harboring EML4-ALK fusion and a G1202R de novo gene mutation

被引：0
|
作者：
Pan, Yue [1 ]
Zeng, Yue [1 ]
Peng, Yurong [1 ]
Liu, Xiaohan [1 ]
Li, Yizheng [1 ]
Wu, Fang [1 ,2 ,3 ,4 ]
机构：
[1] Cent South Univ, Xiangya Hosp 2, Dept Oncol, Changsha 410011, Hunan, Peoples R China
[2] Human Canc Mega Data Intelligent Applicat & Engn, Changsha 410011, Hunan, Peoples R China
[3] Cent South Univ, Xiangya Hosp 2, Human Key Lab Tumor Models & Individualized Med, Changsha 410011, Hunan, Peoples R China
[4] Cent South Univ, Xiangya Hosp 2, Human Key Lab Early Diag & Precis Therapy Lung Ca, Changsha 410011, Hunan, Peoples R China
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 165卷
关键词：
RESISTANCE; MECHANISMS;
D O I：
10.1016/j.ejca.2022.02.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：154 / 156
页数：3
相关论文
共 50 条
  • [1] A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene
    Tanaka, Hisashi
    Hayashi, Akihito
    Morimoto, Takeshi
    Taima, Kageaki
    Tanaka, Yoshihito
    Shimada, Michiko
    Kurose, Akira
    Takanashi, Shingo
    Okumura, Ken
    BMC CANCER, 2012, 12
  • [2] Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement
    Xiao, Zhiwei
    Huang, Xuewu
    Xie, Biyuan
    Xie, Wenzhuan
    Huang, Mengli
    Li, Lizhu
    ONCOTARGETS AND THERAPY, 2020, 13 : 4591 - 4595
  • [3] Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement
    Xiao, Z.
    Huang, X.
    Xie, B.
    Xie, W.
    Huang, M.
    Lin, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S665 - S666
  • [4] Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation
    Kuo, Yao-Wen
    Wu, Shang-Gin
    Ho, Chao-Chi
    Shih, Jin-Yuan
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : 2039 - 2040
  • [5] A CASE OF LUNG ADENOCARCINOMA HARBORING BOTH A KRAS MUTATION AND AN EML4-ALK FUSION GENE WITH RESPONSE TO CRIZOTINIB
    Menefee, Michael E.
    D'Amico, Thomas A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1315 - S1316
  • [6] Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation
    Baglivo, Sara
    Ricciuti, Biagio
    Ludovini, Vienna
    Metro, Giulio
    Siggillino, Annamaria
    De Giglio, Andrea
    Chiari, Rita
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : E145 - E147
  • [7] A CASE OF LUNG ADENOCARCINOMA RESISTANT TO CRIZOTINIB HARBORING KRAS MUTATION AND EML4-ALK FUSION GENE
    Anai, Satoshi
    Suzuki, Kunihiro
    Sueishi, Katsuo
    Harada, Taishi
    Toyokawa, Gouji
    Seto, Takashi
    Takenoyama, Mitsuhiro
    Takayama, Koichi
    Ichinose, Yukito
    Nakanishi, Yoichi
    ANNALS OF ONCOLOGY, 2014, 25
  • [8] Preclinical intracranial activity of NVL-655 in an alectinib-resistant patient-derived model harboring EML4-ALK fusion with G1202R mutation
    Lee, Jii Bum
    Yu, Mi Ra
    Yun, Mi Ran
    Lee, You Won
    Oh, Seung Yeon
    Lee, Eun Ji
    Tangpeerachaikul, Anupong
    Pelish, Henry E.
    Cho, Byoung Chul
    CANCER RESEARCH, 2023, 83 (07)
  • [9] A New Human Lung Adenocarcinoma Cell Line Harboring the EML4-ALK Fusion Gene
    Isozaki, Hideko
    Yasugi, Masayuki
    Takigawa, Nagio
    Hotta, Katsuyuki
    Ichihara, Eiki
    Taniguchi, Akihiko
    Toyooka, Shinichi
    Hashida, Shinsuke
    Sendo, Toshiaki
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (10) : 963 - 968
  • [10] EML4-ALK FUSION GENE IN LUNG ADENOCARCINOMA IN THAILAND
    Prempree, Thongbliew
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1023 - S1024
12345